TargetMol

Unecritinib

Product Code:
 
TAR-T63313
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T63313-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63313-5mg5mg£431.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63313-10mg10mg£600.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63313-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63313-50mg50mg£1,187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63313-100mg100mg£1,581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T63313-500mg500mg£3,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Unecritinib (TQ-B3101) is a potent, orally active, highly potent, blood-brain barrier permeable and low toxic inhibitor of EGFR tyrosine kinase with antitumor activity. Unecritinib inhibited ALK, ROS1 and MET. Unecritinib is a potential compound for the study of solid tumors and relapsed or refractory AlK-positive anaplastic large cell lymphomas.
CAS:
1418026-92-2
Molecular Weight:
492.37
Pathway:
Angiogenesis|JAK/STAT signaling|Tyrosine Kinase/Adaptors
Purity:
0.9916
SMILES:
O([C@H](C)C1=C(Cl)C(F)=CC=C1Cl)C2=CC(=CN=C2NC(C)=O)C3=CN(N=C3)C4CCNCC4
Target:
ALK|EGFR|ROS Kinase|c-Met/HGFR

References

Majeed U, et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108. Yang F, et al. Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors. Front Pharmacol. 2022;12:782518.